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Abstract
Background
Down syndrome is associated with specific cognitive deficits. Alongside this, older adults
with Down syndrome are a high risk group for dementia. The Arizona Cognitive Test Battery
(ACTB), a cognitive assessment battery specifically developed for use with individuals with
Down syndrome, has been proposed for use as outcome measures for clinical trials in this
population. It has not been validated in older adults with Down syndrome. This study aims
to assess the use and validity of the ACTB in older adults with Down syndrome.
Methods
Participants with Down syndrome aged 45 and over were assessed using the ACTB, stan-
dard tabletop tests and informant ratings.
Results
Assessment outcomes of 49 participants were analysed. Of these, 19 (39%) had a diagnosis
of dementia or possible dementia. Most participants were able to attempt most of the tasks,
although some tasks had high floor effects (including CANTAB Intra-Extra Dimensional shift
stages completed and Modified Dots Task). Of the ACTB tasks, statistically significant differ-
ences were observed between the dementia and no dementia groups on CANTAB Simple
Reaction Time median latency, NEPSY Visuomotor Precision—Car and Motorbike and
CANTAB Paired Associates Learning stages completed. No significant differences were
observed for CANTAB Intra-Extra Dimensional Shift, Modified Dots Task, Finger Sequenc-
ing, NEPSY Visuomotor precision—Train and Car and CANTAB Paired Associates Learning
first trial memory score. Several of the tasks in the ACTB can be used in older adults with
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Down syndrome and have mild to moderate concurrent validity when compared to tabletop
tests and informant ratings, although this varies on a test by test basis.
Conclusions
Overall, scores for a number of tests in the ACTB were similar when comparing dementia
and no dementia groups of older adults with Down syndrome, suggesting that it would not
be an appropriate outcome measure of cognitive function for clinical trials of dementia treat-
ments without further modification and validation.
Introduction
Down syndrome is associated with a number of characteristic features, including characteristic
facial features and specific physical health problems, such as cardiac defects, thyroid problems
and gastrointestinal and immunological disorders. It has been estimated to have a rate of
approximately 14 per 10,000 live births in the USA [1] and is the most common genetic cause
of intellectual disability.
Down syndrome is also associated with a specific cognitive profile [2] which includes
impairments in the prefrontal and hippocampal domains [3], such as a relative weakness in
verbal short term memory [4], with disproportionally smaller brain volume in these areas [5].
People with Down syndrome also have smaller cerebellar volumes [6], although the research
on cerebellar cognitive function in humans is limited.
In younger adulthood, it may be that IQ (Intelligence Quotient) in people with Down syn-
drome remains fairly stable [7]. However, it has become more evident that one of the behavioural
phenotypes of older adults with Down syndrome is increased risk of developing dementia [8].
This is often a dementia of Alzheimer's type (DAT). At 65 years of age, the risk for people with
Down syndrome developing dementia has been estimated to be 80% [9], although there is large
variation between individuals—some develop signs and symptoms of Alzheimer’s disease in
their 40s, but there have also been reports of individuals without dementia at age 70 [10].
Dementia is characterised by a decline from baseline functioning in memory and other cog-
nitive and daily living skills. As in the general population, decline in cognitive skills are impor-
tant symptoms when making a diagnosis of dementia in people with Down syndrome, although
there are some differences in the clinical presentation in this population, for example the high
rates of epilepsy seen in those with Down syndrome and dementia [9].
Cognition in older adults with Down syndrome
There are a number of studies that have investigated cognition in older adults with Down syn-
drome with and without dementia. A study by Ball and colleagues which included 25 partici-
pants with Down syndrome and dementia of Alzheimer’s type (DAT) and 78 participants with
Down syndrome without dementia showed that participants with dementia had impaired per-
formance on measures of executive functioning and memory compared to those without
dementia [11]. Cognitive functions have been shown to decline sequentially in people with
Down syndrome, with different cognitive functions being affected at different stages of the
dementia [12]. A longitudinal study in the USA showed severely diminished verbal long term
storage and retrieval processing abilities in those with early stage dementia compared to those
without a diagnosis of dementia [13].
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Older adults with Down syndrome have also been shown to perform worse on cognitive
tests, particularly those requiring planning and attention, when compared to younger adults
with Down syndrome and both older and younger adults with non-Down syndrome intellec-
tual disability [14].
In those with cognitive deterioration, decreases in executive function and significant
changes in behaviour have been shown to occur, which are not just due to the memory decline
[15]. Although forgetfulness and confusion are common early symptoms, general slowness and
frontal lobe related features, including diminished initiative and social withdrawal also present
early in dementia in people with Down syndrome [16], to the extent that adults with Down
syndrome may meet the criteria for a dementia of frontal type before they progress to meeting
the criteria for Alzheimer’s disease [17].
A recent study has identified development of cerebellar motor signs, in particular an ataxic
syndrome, during the progression of dementia and epilepsy in this population [18].
These studies suggest that cognitive tests focused on cognitive abilities associated with pre-
frontal and hippocampal brain areas should help to identify the early stages of dementia in
older people with Down syndrome.
Assessment of cognition
Advances in pharmacological treatments for Alzheimer’s disease and the recent trial of meman-
tine in older adults with Down syndrome [19] have highlighted the need to obtain acceptable,
validated and standardised measures of cognitive function in people with Down syndrome.
These measures can help clarify a diagnosis of dementia, and are also required to measure out-
comes, both clinically and in research, as the emphasis shifts towards prevention and treatment.
Despite a large variety of cognitive assessment tools for diagnosis of DAT in people with Down
syndrome, there is currently no consensus on how best to assess and track decline associated
with dementia in this population [20].
The Arizona Cognitive Test Battery (ACTB) was developed to assess cognitive function in
people with Down syndrome, focusing on cognitive difficulties associated with the prefrontal,
hippocampal and cerebellar areas [21]. It has been validated for use in both laboratory and
home environments and makes use of non-verbal responses, in order to reduce confounding
by poor verbal ability. It is largely based on use of a touchscreen computer interface, and incor-
porates several well-known CANTAB (Cambridge Neuropsychological Test Automated Bat-
tery) cognitive tests. In an attempt to overcome potentially high floor levels in this population,
several of the tasks include measurements of errors as well as measures of success.
The ACTB is becoming increasingly recognised as a useful cognitive assessment battery for
people with Down syndrome [22, 23]. It has been validated in children and adults with Down
syndrome, up until the age of 38. However, it has not been validated in older adults with Down
syndrome, and it is not known if the battery would be of value in assessing for dementia and
whether it can detect differences between older adults with and without dementia.
It is also proposed that the ACTB could be a useful measure of outcomes in treatment trials
in this population, for example of dementia treatments, but the psychometric properties and
floor effects of the ACTB need to be confirmed in older adults.
Aim and Hypothesis
This study aimed to assess the use and validity of the ACTB in older adults with Down syn-
drome (with and without clinical diagnoses of dementia), compared to traditional tabletop
tests and informant ratings.
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Our Primary Hypothesis was that the ACTB is able to detect differences in cognitive func-
tions involving the prefrontal, hippocampal and cerebellar regions between people with Down
syndrome who have dementia and those who do not have dementia.
Materials and Methods
The study was approved by the National Research Ethics Committee and conducted in accor-
dance with the Mental Capacity Act [24]. NHS (National Health Service) Research and Devel-
opment and local NHS site permissions were also granted.
Capacity to consent was assessed according to the Mental Capacity Act [24]. The Mental
Capacity Act has clear specifications about research with participants who may lack capacity.
This includes identifying a consultee in cases where participants lack capacity to consent. Par-
ticipants (or their consultee if the participant lacked capacity) provided written consent. This
consent procedure was approved by the NHS Research Ethics Committee.
Setting
The study was conducted in the Greater London area and surrounding counties. This is an area
with a diverse population, including a large range of ethnic and socio-economic backgrounds.
Recruitment
Professionals working in community intellectual disability teams, a specialist inpatient service,
local care homes and daycare centres were asked to approach service users with Down syn-
drome. Assessments were conducted at a convenient place for participants; this was often at
their home or their day centre.
Participants
Men or women with a clinical diagnosis of Down syndrome, aged 45 or over who fulfilled the
following inclusion criteria were included:
• Participants with stable and treated medical and/or mental health problems.
• Participants with sensory impairments that did not prevent them from being able to partici-
pate in the tasks.
Participants were required to understand simple verbal commands and attempt simple puz-
zles and games.
Exclusion criteria included the following:
• Known, unstable medical problems.
• Known, unstable psychosis or affective disorder.
• Clear history of previous Cerebrovascular Accident (CVA) or significant head injury.
• Participants with sensory impairments that prevented them from being able to participate in
the tasks.
There was high medical and psychiatric co-morbidity in our study sample, which reflects
the high levels of co-morbidity in this population. As this study was designed to be pragmatic,
we had a low threshold for inclusion into the study, and considered referrer or carer report
when considering suitability.
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Data collection
The principle researcher (ASi) met with participants and collected the data in one session if
possible. Participants were offered a break half way through the assessment, or more as
required. Occasionally, due to participant fatigue or other practical issues, data were collected
over several sessions. At the end of the assessment, participants were given a choice of a gift
voucher or small gift of a value of around £10.
Relatives or carers were asked to be present during the meeting and completed informant
ratings while the participant completed the cognitive tests. Around half way through recruit-
ment, the order of the tasks was counter-balanced, to reduce the potential effect of task position
on performance.
Pilot study
An assessment manual was developed by adapting the ACTB manual and selected clinical
tabletop assessments. Tabletop assessments were selected by identifying tests that assessed cog-
nitive abilities associated with similar brain regions as the ACTB (i.e. pre-frontal, hippocampal
and cerebellar regions). Consideration was also given to the feasibility of the task.
Where appropriate, we amended the wording of some of the assessments from American
English and to simpler English (for example, in CANTAB Intra-Extra Dimensional shift (IED),
the instructions to participants was amended from identifying “correct” and “wrong” patterns,
to identifying “right” and “wrong” patterns). The assessment was subsequently piloted on the
first 3 participants. Following this, the CANTAB Motor Screening Task (MOT) task was added
to the computer tasks as an initial teaching task.
Primary outcome
The CANTAB Paired Associates Learning (PAL) was our primary outcome measure. It mea-
sures spatial associative memory. It has been shown to distinguish between those with Alzhei-
mer’s disease and those without Alzheimer’s disease in the general population [25]. It has been
used in research with children and adults with Down syndrome [21, 26, 27, 28, 29] and in clini-
cal trials [30]. The outcome measures used in this study were first trial memory score (the
number of patterns correctly located after the first trial) and stages completed (how many
stages were successfully completed). For both measures, a higher score indicates a better result.
This test is described further in S1 Box.
Measures
S1 Box details the assessments used in this study.
ACTB. At the beginning of the cognitive assessment, we administered the CANTAB
MOT, which is a CANTAB teaching test, designed to assess whether participants are able to
use the touchscreen computer tablet. Participants were asked to press on flashing crosses on
the touchscreen. Participants were given several attempts to do this task. If they were not able
to attempt this task adequately, they were deemed to have failed the teaching stage for the com-
puter tasks and did not attempt the rest of the computer-based tasks.
Subtests of the ACTB include CANTAB PAL (which measures spatial associative memory),
CANTAB IED (measures set-shifting), Modified Dots Task (Cats and Frogs) (measures inhibi-
tory control and working memory), CANTAB Simple Reaction Time (SRT) (originally
designed as a measure of attention, but incorporated into the ACTB as a measure of cerebellar
function), Finger Sequencing Task (Fingertapping) (measures motor sequencing) and NEPSY
Visuomotor Precision (visuo-motor tracking and hand-eye coordination) [31].
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The ACTB also contains a spatial memory task (Virtual Computer Generated Arena),
which was not included in our battery due to inaccuracies in screen resolution, leading to
poorly identifiable visual cues that were essential for validity of the task.
The Modified Dots Task and Finger Sequencing Task have been specifically developed for
the ACTB. The Finger Sequencing Task can be conducted either using a computer mouse or a
lever. Many participants were not familiar with operating a computer mouse, and this was
therefore changed to a lever.
Tabletop tasks. For comparative purposes, we included several established tabletop tests.
These were: NAID Object Memory [32], NAID Memory for Sentences [32], Tower of London
Test [33], Verbal Fluency [34], Finger-Nose Test and Gait Assessment (Timed Get Up and Go
Test) [35]. Object Memory, Memory for Sentences, Verbal fluency and the Tower of London
test are widely used clinically in this population and have previously been used in studies with
older people with Down syndrome [11, 36]. The Tower of London Test used was based upon a
version developed for children [37] and adapted for use with people with intellectual disability.
The Finger-Nose Test is a standardised version which has been used to assess motor coordina-
tion in older adults in the general population [38].
Informant ratings. The informant ratings analysed in this study were the Dementia ques-
tionnaire for people with Learning Disabilities (DLD)[39, 40], which includes a measure of
short term memory and the Behaviour Rating Inventory for Executive Function (BRIEF—Par-
ent Form) [41] for caregiver-reported symptoms of executive dysfunction and other frontal
lobe features.
The BRIEF has been used in research with children and young adults with Down syndrome
[21]. As the BRIEF parent version is designed for use with children, where appropriate, we
adapted the wording to make it more applicable for an adult population.
The NEPSY Visuomotor Precision and BRIEF scores are designed to be transformed to
percentiles using population norms for children. We therefore report raw scores only in our
analyses.
For validity reasons, BRIEF questionnaires that had more than 14 questions not answered
were not used in the analysis. Where no answers were provided for subsections, results are not
reported.
Other assessments. The K-BIT II (Kaufman Brief Intelligence Test II) was used as an
assessment of intelligence [42]. This generates separate verbal and non verbal raw subscales,
which are combined to give a total raw score which is often used in analysis for individuals
with intellectual disabilities as conversion of raw scores to population norms would result in a
large proportion of participants scoring at floor.
Demographic and other relevant information, including severity of intellectual disability,
medical history and pharmacological treatment was also collected. Severity of intellectual dis-
ability was recorded from informant report or case notes.
Dementia diagnosis
Dementia diagnosis according to informant report was recorded at the time of assessment.
Where applicable, the status of a dementia diagnosis at the time of assessment (or subsequently
made by the treating clinician directly based on the findings of the assessment) was clarified
from the clinical notes and/or by discussing this with the participant’s treating clinician. A con-
sensus dementia diagnosis was then agreed by two members of the research team (ASi and ASt;
both are specialist Intellectual Disability psychiatrists), taking into account the treating clini-
cian’s dementia diagnosis as well as other relevant factors, for example, history of cognitive and
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functional decline and/or new onset of epilepsy. Clinical diagnosis of dementia in this popula-
tion has been shown to be valid and reliable [43].
Participants were categorised into either a “dementia” or “no dementia group”. Those in the
dementia group had a diagnosis of dementia or possible dementia. Some participants in the no
dementia group had symptoms of cognitive concern, which may have been explained by other
factors (such as physical or mental health problems) or were not enough to warrant a diagnosis
of dementia. When reporting and discussing results, we will refer to the two groups as “demen-
tia” and “no dementia” groups.
Analysis
Numerical data were summarised using mean, standard deviation, median and range. Categor-
ical data were summarised using count and percentages. Differences between the dementia and
non-dementia groups were assessed using Chi-square test, Fisher's exact or Mann Whitney test
as appropriate. For the cognitive tests, estimates of the difference and corresponding 95% con-
fidence interval were presented. Correlation was used to assess concurrent validity.
As this was an exploratory study, p-values were not adjusted for multiple testing and there-
fore significant results should be interpreted with caution.
Analyses were undertaken in SPSS Version 21 [44] and Stata Version 12 [45].
Participant details
A total of 50 participants were recruited. We conducted genetic analyses using a SNP array
(Single Nucleotide Polymorphism array) on 39 individuals. Of these, 1 participant had disomy,
3 had mosaicism (including some with low level mosaicism) and rest had full trisomy. The par-
ticipant with disomy was subsequently removed from analyses (see S1 Fig), as genetic testing
did not show any evidence that the participant had Down syndrome. In total, five participants
had mosaic Down syndrome, either documented in the clinical notes or confirmed with genetic
testing; two participants with mosaicism had a diagnosis of dementia.
The mean age at first assessment was 52.7 years (SD: 6.06, range: 45.1–64.9 years), with
mean age 55.6 years (SD 6.77) for those in the dementia group compared to 50.9 years (SD:
4.83) for those in the no dementia group. There was a significant difference in age between the
two groups (p = 0.027).
Results
S1 Fig summarises the flow of participants in the study.
Demographic characteristics and medical conditions
Table 1 shows the demographic characteristics and common medical conditions of the study
sample.
Five participants had documented hypercholesterolaemia and one had a history of hyper-
tension. One participant had a diagnosis of diabetes (diet controlled Type II diabetes) and two
were smokers. Thirteen participants had skin problems, including psoriasis and dermatitis.
Five participants had abdominal problems, including abdominal pain and irritable bowel syn-
drome. Two participants were on anticoagulant treatment for deep vein thrombosis (DVT).
One participant had a history of Bipolar Affective Disorder, and was receiving medication.
Other mental health diagnoses recorded amongst participants included anxiety, OCD symp-
toms and behavioural problems.
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Use of the ATCB
In order to evaluate feasibility of the cognitive tests, we initially examined the proportion of
participants who were able to attempt each of the ACTB and tabletop tasks (i.e. those who were
able to start each of the tasks, after completing the teaching task, if appropriate). The number
of participants that attempted the testing phase of the ACTB tasks ranged from 39 (81.3%) for
the Modified dots task to 46 (93.9%) for the CANTAB SRT. The number of participants that
attempted the testing phase of the tabletop tasks ranged from 34 (69.4%) for Object memory to
43 (87.8%) for Verbal fluency. Ten (52.6%) people with dementia were able to attempt all the
ACTB tasks and ten (52.6%) were able to attempt all the tabletop tasks. 23 (76.7%) people in
the no dementia group were able to attempt all the ACTB tasks and 21 (70.0%) attempted
Table 1. Summary characteristics of the study sample (N = 49).
Whole group/n (%) Dementia/n (%) No Dementia/n (%) P value
Gender
Male 23/49 (46.9%) 12/19 (63.2%) 11/30 (36.7%)
Female 26/49 (53.1%) 7/19 (36.8%) 19/30 (63.3%) 0.070a
Age
Below 50 20/49 (40.8%) 6/19 (31.6%) 14/30 (46.7%)
50–54 14/49 (28.6%) 3/19 (15.8%) 11/30 (36.7%)
55–59 5/49 (10.2%) 2/19 (10.5%) 3/30 (10.0%)
60 and over 10/49 (20.4%) 8/19 (42.1%) 2/30 (6.7%) 0.027b
Level of ID
Mild 13/35 (37.1%) 5/14 (35.7%) 8/21 (38.1%)
Moderate/Severe 22/35 (62.9%) 9/14 (64.3%) 13/21 (61.9%) 0.886a
Ethnic origin
White 41/48 (85.4%) 17/19 (89.5%) 24/29 (82.8%)
African/Afro-Caribbean 3/48 (6.3%) 1/19 (5.3%) 2/29 (6.9%)
Other 4/48 (8.3%) 1/19 (5.3%) 3/29 (10.3%) 0.839c
Type of Accommodation
With family or friends 14/49 (28.6%) 6/19 (31.6%) 8/30 (26.7%)
Adult placement 6/49 (12.2%) 1/19 (5.3%) 5/30 (16.7%)
Sheltered/Supported/ Residential Care 29/49 (59.2%) 12/19 (63.2%) 17/30 (56.7%) 0.534c
Medical conditions
Thyroid problems 20/48 (41.7%) 7/18 (38.9%) 13/30 (43.3%) 0.762a
Epilepsy 9/48 (18.8%) 5/19 (26.3%) 4/29 (13.8%) 0.451c
Falls 9/44 (20.5%) 4/16 (25.0%) 5/28 (17.9%) 0.702c
Congenital Cardiovascular problems 5/47 (10.6%) 2/18 (11.1%) 3/29 (10.3%) 1.000c
Hearing problems 8/46 (17.4%) 5/18 (27.8%) 3/28 (10.7%) 0.232c
Visual problems 23/48 (47.9%) 10/19 (52.6%) 13/29 (44.8%) 0.597a
Family history of dementia 7/33 (21.2%) 1/12 (8.3%) 6/21 (28.6%) 0.223c
Psychosis 7/45 (15.6%) 1/17 (5.9%) 6/28 (21.4%) 0.227c
Depression 15/45 (33.3%) 4/17 (23.5%) 11/28 (39.3%) 0.227a
a Chi Squared value
b Independent-Samples Mann-Whitney U Test
c Fisher’s exact value
doi:10.1371/journal.pone.0153917.t001
Cognitive Deficits, Dementia and Down Syndrome
PLOSONE | DOI:10.1371/journal.pone.0153917 May 12, 2016 8 / 18
all the tabletop tasks. Reasons for participants not being able to attempt tasks included not
passing the teaching stage, technical problems or the participant declining to attempt the task.
Table 2 shows distribution data for the specific cognitive assessments and differences
between the dementia and no dementia groups. It also shows percentage of participants at
floor and ceiling for each of the cognitive tasks. CANTAB IED stages completed and Modified
Dots Task had particularly high percentages of participants at floor. See Box 1 for further
details regarding calculation of floor and ceiling levels.
Differences between dementia and no dementia groups
Of the ACTB tasks, significant differences between the dementia and no dementia groups were
found for CANTAB SRT median latency, NEPSY Visuomotor Precision—Car and Motorbike
and CANTAB PAL stages completed. However, 95% confidence intervals for the median dif-
ference did not include zero only for CANTAB SRT median latency and NEPSY Visuomotor
Precision—Car and Motorbike. Of the other tasks, 95% confidence intervals did not include
zero for K-BIT II total and verbal subscale raw scores, Verbal Fluency raw score, Object Mem-
ory, and DLD short term memory, sum of cognitive scores and total score, with the no demen-
tia group performing better on these tests.
Validity of the ACTB
In order to assess concurrent validity, we calculated correlation coefficients between measures
that assessed the same or similar areas of cognition. That is, we compared prefrontal, hippo-
campal and cerebellar tasks from the ACTB with appropriate measures from the tabletop tests
and informant ratings. The results are detailed below.
Validity—Prefrontal measures. Some of the CANTAB IED scores showed a significant
mild to moderate correlation with Verbal fluency adjusted and Tower of London stages com-
pleted scores (from 0.40 to +/-0.45 depending on outcome measure used). The Modified dots
task showed a significant moderate correlation with Verbal fluency adjusted and Tower of Lon-
don stages completed (from 0.48 to 0.63 depending on outcome measure used). Very few of
the BRIEF scales were significantly correlated with the CANTAB IED scores (only BRIEF
working memory scores showed a mild to moderate correlation with some of the IED outcome
measures, from -0.44 to 0.35) and none of the Modified dots scores were significantly corre-
lated with the BRIEF scores.
Validity—Hippocampal measures. Both of the CANTAB PAL outcome measures were
significantly correlated with Object memory (with both having a correlation of 0.35), and with
DLD scores (from -0.45 to -0.56). There was no significant correlation between either of the
CANTAB PAL measures and memory for sentences.
Validity—Cerebellar measures. There was a mild to moderate significant correlation
between CANTAB SRT median latency and Finger-nose (-0.51) and Gait assessment (0.38)
measures. There were also significant correlations between the NEPSY visuomotor precision
outcome measures and the Finger-nose and Gait assessment measures (with the absolute mag-
nitude of the correlation ranging from 0.43 to 0.51). The Finger sequencing task was signifi-
cantly correlated with the Finger-nose task (0.42), but not Gait assessment.
Discussion
We conducted a validation study of cognitive tests in older individuals with Down syndrome,
with and without dementia. Although the majority of participants were able to attempt most of
the tasks, some tasks had a large number of participants at floor. Furthermore, of the ACTB
tasks, the only tests that were able to detect significant differences between the dementia and
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Table 2. Distribution data for cognitivemeasures and differences in cognitive tests between dementia and no dementia groups.
Dementia (n = 19) No Dementia (n = 30)
n Mean Median Number
at ﬂoor
Number
at ceiling
n Mean Median Number
at ﬂoor
Number
at ceiling
Median
difference
P
value c
(SD) (Range) (%) (%) (SD) (Range) (%) (%) (95% CI)
ACTB Tests:
CANTAB PAL ﬁrst
trial memory
score
15 0.93 1 7 0 29 2.97 1 9 0 -1 0.099
(1.16) (0–4) (46.7%) (0.0%) (3.77) (0–15) (31.0%) (0.0%) (-2 to 0)
CANTAB PAL
stages completed
15 1.40 2 4 0 29 3.21 2 2 2 -1 0.011
(1.12) (0–4) (26.7%) (0.0%) (2.40) (0–8) (6.9%) (6.9%) (-2 to 0)
CANTAB IED
stages completed
15 0.60 0 9 0 29 2.41 1 14 0 0 0.159
(0.83) (0–2) (60.0%) (0.0%) (3.11) (0–8) (48.3%) (0.0%) (-2 to 0)
IED errors block 1 15 16.53 19 n/a 2 29 13.17 13 n/a 4 3 0.405
(10.71) (0–32) (13.3%) (11.49) (0–29) (13.8%) (-3 to 10)
Modiﬁed Dots
Task 2nd stage
11 0.36 0.33 10 0 21 0.46 0.33 14 4 0 0.876
(0.16) (0.00–
0.58)
(90.9%) (0.0%) (0.35) (0.08–
1.00)
(66.7%) (19.0%) (-0.33 to
0.17)
Modiﬁed Dots
Task 3rd stage
11 0.32 0.36 10 0 21 0.42 0.42 15 0 -0.09 0.155
(0.14) (0.12–
0.52)
(90.9%) (0.0%) (0.19) (0.03–
0.91)
(71.6%) (0.0%) (-0.21 to
0.03)
CANTAB SRT
median latency
17 1556.5 1626 n/a n/a 27 1186.8 1031 n/a n/a 392 0.049
(559.8) (640–
2350)
(616.5) (351–
2408)
(8.5 to 757)
Finger
Sequencing task
14 1.50 1 1 1 28 1.86 2 0 4 0 0.284
(1.02) (0–4) (7.1%) (7.1%) (1.04) (1–4) (0.0%) (14.3%) (-1 to 0)
NEPSY
Visuomotor
Precision train
and car
10 8.50 10 0 0 25 11.08 11 0 0 -3 0.303
(4.65) (1–14) (0.0%) (0.0%) (6.34) (1–21) (0.0%) (0.0%) (-7 to 1)
NEPSY
Visuomotor
Precision car and
motorbike
10 3.20 3 0 0 23 9.87 3 0 0 -3 0.013
(1.99) (1–8) (0.0%) (0.0%) (8.46) (2–28) (0.0%) (0.0%) (-11 to -1)
Tabletop Tests:
Verbal Fluency
raw score
14 2.93 3 4 n/a 29 6.3 6 2 n/a -3 0.006
(2.70) (0–9) (28.6%) (4.10) (0–17) (6.9%) (-5 to -1)
Verbal Fluency
adjusted
14 0.93 1 4 0 29 1.79 2 2 0 -1 0.002
(0.73) (0–2) (28.6%) (0.0%) (0.86) (0–4) (6.9%) (0.0%) (-1 to 0)
Tower of London
stages completed
16 1.56 2 5 0 26 2.31 2 1 6 -1 0.102
(1.26) (0–3) (31.3%) (0.0%) (1.19) (0–4) (3.8%) (23.1%) (-2 to 0)
Tower of London
points
11 3.27 3 7 0 25 3.88 3 7 2 0 0.710
(2.49) (0–7) (43.8%) (0.0%) (3.32) (0–10) (26.9%) (7.7%) (-2 to 2)
Object Memory 12 3.50 3.50 7 0 22 6.41 6.50 3 2 -3 0.007
(2.94) (0–9) (43.8%) (0.0%) (2.40) (1–10) (12.0%) (8.0%) (-5 to -1)
Memory for
Sentences
14 9.71 11 3 0 28 14.64 10 1 0 -2 0.362
(6.37) (0–21) (18.8%) (0.0%) (12.24) (1–44) (3.4%) (0.0%) (-9 to 3)
Finger-nose 14 4.93 4.50 0 n/a 26 7.23 6.0 0 n/a -2 0.130
(2.92) (1–10) (0.0%) (4.50) (2–19) (0.0%) (-4 to 0)
Gait assessment 12 15.76 14.55 3 n/a 26 14.08 11.96 0 n/a 2.35 0.155
(4.26) (7.82–
23.17)
(20%) (5.19) (6.53–
25.93)
(0.0%) (-1.89 to
4.74)
(Continued)
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no dementia groups were the CANTAB Simple Reaction Time median latency, NEPSY Visuo-
motor Precision—Car and Motorbike and CANTAB Paired Associates Learning stages com-
pleted. In practical terms, the median difference and 95% confidence intervals show the
magnitude of the difference in scores between the dementia and non dementia groups. When
considering median difference, only CANTAB SRT and NEPSY Visuomotor precision—car
and motorbike have 95% confidence intervals that do not include zero, and scores for a number
of tests in the ACTB were similar when comparing dementia and no dementia groups. How-
ever, the DLD, for all three scales analysed, had p values of<0.001 and 95% confidence inter-
vals that did not include zero, reflecting the large differences in DLD scores between the
dementia and non-dementia groups.
Strengths and limitations
This is the first study to fully assess the use of the ACTB in older adults with Down syndrome
and compare its use in those with and without dementia. The study was designed to be pragmatic
Table 2. (Continued)
Dementia (n = 19) No Dementia (n = 30)
n Mean Median Number
at ﬂoor
Number
at ceiling
n Mean Median Number
at ﬂoor
Number
at ceiling
Median
difference
P
value c
(SD) (Range) (%) (%) (SD) (Range) (%) (%) (95% CI)
Informant ratings:
BRIEF
Shift 10 16.40 15.50 24 16.25 17.00 0 0.867
(3.72) (9–22) (4.45) (8–23) (-3 to 2)
Inhibit 11 16.55 17.00 24 15.75 15.00 1 0.636
(3.73) (11–22) (4.10) (10–24) (-2 to 4)
Working memory 11 22.00 20.00 24 20.33 21.00 1 0.587
(4.86) (15–30) (5.21) (10–30) (-2 to 5)
BRI 10 52.90 54.00 24 49.42 51.50 4 0.423
(10.49) (36–66) (11.75) (28–73) (-6 to 12)
DLD
Short Term
Memory (STM)
19 8.47 10 30 2.67 2.00 6 <0.001
(4.01) (0–13) (3.03) (0–11) (4 to 9)
Sum Cognitive
Scores
19 26.47 26 30 12.43 12.50 15 <0.001
(8.90) (7–38) (9.89) (1–33) (9 to 20)
Total Score 19 46.53 43 30 25.10 25.50 23 <0.001
(17.35) (14–74) (15.11) (2–62) (10 to 33)
K-BIT II:
Total raw score 19 9.74 6 0 0 30 23.17 14 0 0 -7 0.005
(11.06) (1–49) (0.0%) (0.0%) (19.50) (3–63) (0.0%) (0.0%) (-22 to -2)
Verbal subscale
raw score
19 6.53 4 1 0 30 16.37 10 0 0 -6 0.002
(7.61) (0–34) (5.3%) (0.0%) (13.33) (1–47) (0.0%) (0.0%) (-13 to -2)
Non verbal
subscale raw
score
19 3.21 2 4 0 30 6.80 3 5 0 -1 0.184
(4.16) (0–15) (21.1%) (0.0%) (6.92) (0–20) (16.7%) (0.0%) (-8 to 0)
c Independent samples Mann Whitney U test
doi:10.1371/journal.pone.0153917.t002
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(i.e. conducted in real-life conditions as opposed to laboratory conditions) so that results could
be directly applied to this population. It used manualised standardised assessments of cognitive
skills in 49 adults with Down syndrome, a reasonable sample size when considering the difficul-
ties of recruitment in this population.
Statistical analyses were hypothesis driven and limited to specific statistical tests that were
relevant to the research question, thus reducing the possibility of multiple analyses and type I
errors.
Regarding measurement of concurrent validity, we assessed the ACTB tests against tabletop
tasks as well as informant ratings. The use of informant ratings provided a different measure of
comparison that was less likely to be influenced by participant performance.
There are a number of limitations to this study, which mainly arise from the logistical issues
of working with this population. There was a significant difference in age between the dementia
and no dementia groups. This is to be expected, as it is well known that increasing age is associ-
ated with increasing risk of dementia in the general population [46], and in those with Down
syndrome [27].
A larger proportion of the no dementia group were able to attempt the tasks as compared to
the dementia group. Although breaks were given during the assessment and, on occasion, sec-
ond and third assessments were arranged, the requirements to concentrate and pay attention
to the tasks were sometimes difficult for participants. As the study aimed to focus on the
ACTB, participants were encouraged to attempt the ACTB tasks, which may explain why a
greater proportion attempted the ACTB tasks as opposed to the other tasks. The tasks were
counterbalanced halfway through the assessment period, rather than alternating from the
beginning of the study, which may have introduced some bias into the study.
We used clinical diagnoses to categorise participants into the “dementia” and “no dementia”
groups. Some participants in the “no dementia” group may since have developed dementia.
Non-parametric methods were considered in the absence of suitable transformations of the
data. These are less sensitive to extreme values, but are also potentially less robust, as they rely
on ranking rather than the raw values of the data. Estimates (mean and median) and 95% con-
fidence intervals of the median difference are presented in order to indicate the magnitude of
the difference. As this was an exploratory study, and p values were not adjusted for multiple
testing, results may need to be interpreted with caution.
Box 1. Floor and Ceiling Levels
For the majority of the tasks, floor was calculated as a score of zero (for: K-BIT II total
raw score, K-BIT II verbal and non verbal subscales, CANTAB PAL stages completed and
first trial memory score, CANTAB IED stages completed, Finger sequencing task, NEPSY
visuomotor precision, Verbal fluency raw score and adjusted and Finger-nose test).
For NAID Object Memory, NAID Memory for Sentences, Tower of London points
and stages completed, floor was calculated as a score of zero and/or did not pass teaching
stage.
For Gait assessment, floor was calculated as being unable to mobilise without assistance.
In the Modified Dots Task, floor was calculated as 50% or under (as 50% of responses
should be correct by chance alone). CANTAB SRT median latency is measured in units
of time and, as it is on a continuum, floor and ceiling levels are not applicable.
Where applicable, ceiling levels were calculated as maximum possible score.
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Floor Effects
The majority of data in this study did not fit a normal distribution, and much of the data was
skewed. This is likely to be related to cognitive weaknesses in this group, resulting in large
numbers of participants at floor for a number of outcome measures.
High floor levels have been a finding in other studies with similar populations. In a recent
multinational study of adolescents and younger adults with Down syndrome, floor and ceiling
effects were found in some of the cognitive tests, with some differences between the two groups
[47]. In one large cross-sectional study of older adults with Down syndrome, the majority of
participants with severe intellectual disability were unable to perform above floor on the major-
ity of neuropsychological tests and were subsequently excluded from further analyses [11].
Interestingly, in a recent Spanish study of younger adults with Down syndrome, ceiling effects
were found for PAL number of stages completed and SRT percent of correct answers [29].
Differences between dementia and no dementia groups
In this study, of the 12 cognitive tests that were evaluated, only 5 were found to show a signifi-
cant difference between the dementia and no dementia groups and only three of these tests
were from the Arizona Cognitive Test Battery. Given that a diagnostic characteristic of demen-
tia is deterioration in cognitive skills, we would have expected more cognitive differences to be
detected between the dementia and no dementia groups.
One explanation for our findings may be that in this age range most individuals with Down
syndrome are already showing significant cognitive deficits associated with Alzheimer’s disease
despite not meeting the clinical threshold used for diagnosis. The similarities in the results of
the cognitive tests may therefore reflect underlying similarities between the two groups.
As scores for a number of tests in the ACTB were similar when comparing dementia and no
dementia groups, this indicates that some components of the ACTB may not, in its current
form, be a useful cognitive battery in older individuals with Down syndrome but may need to
be further adapted for use in this population.
Comparison with cognitive function in children and younger adults with
Down syndrome
Our sample had lower mean K-BIT II raw scores compared to that in the ACTB paper.
When comparing the CANTAB PAL first trial memory score results in our study to that in
the original ACTB study, the mean was much lower in our study (2.27 compared to 7.42),
which is likely to be a reflection of the differences in memory related to the difference in ages of
people with Down syndrome in the two studies. Also, the percentage of participants at the
floor of the CANTAB PAL first trial memory score was much higher in our study (36.4% ver-
sus 14.1%), which may explain why the distribution of results was not normally distributed.
The means of the Modified Dots Task were also lower than the means of the same tests
reported originally [21].
Furthermore, when comparing the means of the CANTAB SRT median latency and NEPSY
Visuomotor Precision—train and car in our study to the original ACTB study, participants in
our study showed poorer performance. This may highlight decline in fine motor skills with age
in Down syndrome, though it is also possible that the original sample used for the development
and validation of the ACTB was not typical of general population of individuals with Down
syndrome.
Two recent cross sectional studies on cognition in adults with Down syndrome without
dementia reflect our observation that in older adulthood, most individuals with Down syndrome
Cognitive Deficits, Dementia and Down Syndrome
PLOSONE | DOI:10.1371/journal.pone.0153917 May 12, 2016 13 / 18
may already show significant cognitive deficits associated with DAT, reporting a significant age-
related decline in cognitive function and social adaptation skills [48] and lower neuropsychologi-
cal function and adaptive skills in adults with Down syndrome over 40 years old, compared to
those under 40 [49]. Language and short term memory, frontal lobe functions, visuospatial abili-
ties and adaptive behaviour are particularly affected [49].
Cognitive function in adults with Down syndrome and dementia
Significant cognitive differences using other test batteries have been found between older and
younger adults with Down syndrome [14] and between individuals with Down syndrome with
and without dementia [11]. These included tests of executive function and memory, including
Tower of London, Verbal fluency, Object memory and Memory for sentences [11]. In our
study, we also found a statistically significant difference comparing the dementia and no
dementia groups on Object memory and Verbal fluency, but did not identify significant differ-
ences in the Tower of London or Memory for Sentences tasks.
The sample group in our study is older, and those in the no dementia group may already
have experienced some of the changes in executive function and behaviour seen in the early
stages of cognitive deterioration. However, we have also deliberately selected a sample that is
representative of the older population with Down syndrome, and included individuals with a
broader range of disability. This may explain why a number of participants, including those in
the no dementia group, performed at floor for a number of the tests.
Although this study was not designed to measure attention in older people with Down syn-
drome and dementia, it became evident during the course of data collection that a number of
participants were not able to attempt or complete the tasks due to limited attention, which is
an important factor to consider in the design of future test batteries.
Das et al found that older adults with Down syndrome performed more poorly on cognitive
tasks, particularly those that required planning and attention when compared to older adults
with intellectual disability not due to Down syndrome and younger adults with intellectual dis-
ability both with and without Down syndrome [14]. Krinsky-McHale et al have suggested the
addition of a selective attention task (a paper and pencil picture cancellation task) to a neuro-
psychological battery for dementia in Down syndrome and have found that changes in perfor-
mance can be observed approximately 2 years before a clinical diagnosis of dementia [50].
Like the findings in Deb’s qualitative study [16], which documents general slowness in their
study sample, in our study we also found that participants were generally slow on motor reac-
tion time tasks, as reflected in the long median latency times seen in the CANTAB SRT.
In our study, there were significant differences between the dementia and no dementia
groups in all three of the DLD outcome measures we used. In McCarron’s longitudinal study
using objective and informant-based tests, the DLD was found to be most sensitive to tracking
change in symptoms over time prior to a diagnosis of dementia [9].
Recommendations for cognitive test battery for older adults with Down
syndrome
We have made some suggestions regarding which of the tests in this battery are most useful
when assessing cognitive skills in older people with Down syndrome. These are detailed in
Table 3.
In clinical practice, logistical issues such as access to hardware and software may limit the
use of computer-based tests such as those in the CANTAB battery.
We suggest that cognitive test batteries to track change in older adults with Down syndrome
need to include informant-rated tools.
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Conclusions
Some tests in the ACTB test battery (CANTAB PAL, CANTAB SRT, NEPSY Visuomotor
Precision, Finger Sequencing) appear to be feasible and valid in older adults with Down syn-
drome, although for certain subtests (including CANTAB IED, Modified Dots Task, Finger
Sequencing, NEPSY Visuomotor precision—Train and Car and CANTAB PAL first trial mem-
ory score), scores may be similar when comparing those with and without dementia. This may
be explained by a minimal difference in specific cognitive skills between those with a diagnosis
of dementia and those without.
Several of the tests used in this study may be helpful in assessing cognitive skills and cogni-
tive decline in older people with Down syndrome and may be useful in preventative treatment
trials (these include CANTAB PAL, CANTAB SRT, NEPSY Visuomotor Precision, Verbal Flu-
ency, Tower of London, NAID Object Memory, DLD, K-BIT II). However, the ACTB as a
whole is unlikely to show change in cognitive skills in those who have a diagnosis of dementia
and it may be necessary to also use informant-rated assessment tools in the Down syndrome
population with dementia. In addition it may be helpful to consider including an assessment of
attention in any cognitive battery used with older adults with Down syndrome.
Nevertheless, repeated assessments over time of specific cognitive skills using subtests of the
ACTB will be useful in future research including epidemiological studies and clinical trials.
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Table 3. Recommended cognitive tests to use in a cognitive test battery for older people with Down
syndrome.
Test Outcome
measures
Comments
CANTAB PAL - Stages
completed
Used in many similar studies
CANTAB SRT - Median latency Difference in scores seen between dementia and no
dementia groups.
NEPSY Visuomotor
precision
- Train and Car Difference in scores for Car and Motorbike seen between
dementia and no dementia groups.
- Car and
Motorbike
Verbal ﬂuency - Raw score Difference in scores for raw score seen between dementia
and no dementia groups. Easy to administer. Used in other
studies.
Tower of London - Stages
succeeded on
Easy to administer. Used in many other studies.
NAID Object memory Difference in scores seen between dementia and no
dementia groups. Easy to administer. Used in other studies.
DLD - Sum of cognitive
scores
Difference in scores seen between dementia and no
dementia groups. Easy to administer. Used in many other
studies.
- Total score
K-BIT II -Total raw score Difference in scores seen between dementia and no
dementia groups for total raw score and verbal subscale.
Easy to administer. Used in other studies.
- Verbal subscale
doi:10.1371/journal.pone.0153917.t003
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